designer estrogen

designer estrogen

SERM, see there.
References in periodicals archive ?
Definitions of the perfect designer estrogen may vary depending on the patient.
Large-scale clinical trials of a designer estrogen known as idoxifene were recently canceled after several years because, like estrogen and tamoxifen, the compound seemed to boost a woman's chance of developing endometrial cancer.
One could make the case that until long-term trials are completed, physicians shouldn't prescribe any designer estrogen for extended use, she says.
Many companies hope to develop a designer estrogen, or selective estrogen receptor modulator (SERM), that men can take to prevent heart disease.
This synthetic hormone may lead the way to other compounds, in the group known as designer estrogens, that will be even more selective.
Two designer estrogens are currently on the market, however, one to treat breast cancer and one to prevent bone loss that can lead to the brittle-bone disease osteoporosis.
The excitement over designer estrogens began with what is known as the tamoxifen paradox.
While some scientists were examining the molecular actions of designer estrogens, others were exploring the effects of these drugs on patients.
Raloxifene's apparent ability to prevent breast cancer provides "solid encouragement" that the first designer estrogens will live up to their promise, Franks says.
A growing knowledge of how designer estrogens work "intensifies the anticipation of finding something even better than raloxifene," Franks says.
At menopause, women should consider hormone replacement (estrogen) or the new designer estrogen Raloxifene to reduce the chance of bone loss.
However, the section on breast cancer screening is weak and includes, for example, a short and inadequate discussion of designer estrogens and their role in breast cancer risk reduction.